INTRODUCTION
============

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019 in Wuhan, Hubei Province, China.[@B1] This disease has spread rapidly to other regions around the world, including the Western Pacific, Europe, Eastern Mediterranean, Americas, and Southeast Asia. The World Health Organization declared COVID-19 a pandemic on March 12, 2020. By April 19, 2020, approximately 2.28 million cases had been diagnosed with 155,124 deaths worldwide.

Although 81% of COVID-19 cases are mild, 14% are severe, and 5% are critical. The fatality rate is about 50.0% in critical cases.[@B2] A number of factors associated with severe COVID-19 have been identified from China. Older age, male sex, presence of comorbidities, low oxygen saturation, and abnormal lab findings (high lactate dehydrogenase \[LDH\], high procalcitonin, low CD4 cell count, low albumin level) were shown to be risk factors for severe COVID-19.[@B3][@B4][@B5][@B6][@B7][@B8]

However, patient- and disease-related factors vary from region to region, and these factors may be associated with the clinical severity of COVID-19. There have been no studies regarding prognostic factors for severe disease in COVID-19 patients in Korea. This study was performed to identify prognostic factors for severe disease in patients with COVID-19 in Daegu, Korea.

METHODS
=======

Study design and participants
-----------------------------

This was a retrospective observational study of 110 patients with confirmed COVID-19 at Yeungnam University Medical Center, Daegu, Korea, from February 19, 2020 to April 15, 2020. During the study period, all adult patients (age ≥ 18 years) with COVID-19 who were hospitalized via the emergency room or outpatient department were eligible for inclusion.

Data collection and definitions
-------------------------------

Demographic, clinical, laboratory, treatment, and outcome data were collected from the electronic medical records of the participants. Demographic and clinical data included age, sex, comorbidities, symptoms and vital signs on admission, and treatment in the hospital. Laboratory data consisted of complete blood count, blood biochemistry, and infection-related biomarkers. Peripheral oxygen saturation was measured by pulse oximetry immediately on hospitalization of the patient. In-hospital case fatality rate was monitored until the final date of follow-up. The data were collected and analyzed by all authors.

Severe disease was defined as a composite outcome of acute respiratory distress syndrome (ARDS), intensive care unit care, or death. ARDS was diagnosed according to the Berlin definition.[@B9] SARS-CoV-2 infection was confirmed by real-time reverse transcription polymerase chain reaction assay of nose and/or throat swap samples.

Statistical analysis
--------------------

Continuous variables are expressed as means ± standard deviation and were compared by Student\'s *t-*test or the Mann-Whitney U test. Categorical variables are described as number (%) and were compared by the χ^2^ test or Fisher\'s exact test. Univariable logistic regression analysis was performed to identify prognostic factors of severe COVID-19. Multivariable logistic regression analysis was conducted with variables that showed *P* \< 0.05 in univariable analysis. We excluded variables from the univariable analysis if the number of events was too small for calculation and if there was no marked difference between two groups. In all analyses, two-tailed *P* \< 0.05 was taken to indicate statistical significance. All statistical analyses were performed using SPSS software (ver. 24.0; SPSS Inc., Chicago, IL, USA).

Ethics statement
----------------

This study was conducted in accordance with the tenets of the Declaration of Helsinki and was reviewed and approved by the Institutional Review Board (IRB) of Yeungnam University Hospital (YUH IRB 2020-03-057). The requirement for informed consent was waived because of the retrospective study design. The final follow-up date was April 15, 2020.

RESULTS
=======

Demographic and clinical characteristics
----------------------------------------

After excluding seven patients who were transferred to other hospitals, 110 hospitalized patients with confirmed COVID-19 were included in this study ([Fig. 1](#F1){ref-type="fig"}). Baseline characteristics of all patients are summarized in [Table 1](#T1){ref-type="table"}. The mean age was 56.9 ± 17.0 and 62 patients (56.4%) were women. Forty-nine patients (44.5%) had comorbidities, of which hypertension was the most common (33.6%) followed by diabetes mellitus (26.4%). The most frequently presenting symptoms were fever (56.4%) and cough (52.7%).
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###### Baseline characteristics of the study participants with COVID-19
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  Characteristics            All patients (n = 110)            Severe patients (n = 23)   Non-severe patients (n = 87)   *P* value      
  -------------------------- --------------------------------- -------------------------- ------------------------------ -------------- ----------
  Age, yr                    56.9 ± 17.0                       68.0 ± 11.9                53.9 ± 17.0                    \< 0.001       
  Sex                                                                                                                    0.051          
                             Male                              48 (43.6)                  14 (60.9)                      34 (39.1)      
                             Female                            62 (56.4)                  9 (39.1)                       53 (60.9)      
  Comorbidities              49 (44.5)                         13 (57)                    36 (57)                        0.144          
                             Cardiovascular disease            10 (9.1)                   1 (4.3)                        9 (10.3)       0.352
                             Cerebrovascular disease           4 (3.6)                    1 (4.3)                        3 (3.4)        0.614
                             Chronic lung disease              4 (3.6)                    2 (8.7)                        2 (2.3)        0.192
                             Dementia                          4 (3.6)                    2 (8.7)                        2 (2.3)        0.614
                             Diabetes mellitus                 29 (26.4)                  14 (60.9)                      15 (17.2)      \< 0.001
                             Hypertension                      37 (33.6)                  12 (52.2)                      25 (28.7)      0.033
                             Connective tissue disease         1 (0.9)                    0 (0)                          1 (1.1)        0.791
                             Liver disease                     1 (0.9)                    0 (0)                          1 (1.1)        0.192
                             Malignancy                        6 (5.5)                    1 (4.3)                        5 (5.7)        0.633
                             Parkinson\'s disease              1 (0.9)                    0 (6.7)                        1 (1.1)        0.209
  Symptoms on admission                                                                                                                 
                             Fever                             62 (56.4)                  14 (60.9)                      48 (55.2)      0.402
                             Cough                             58 (52.7)                  10 (43.4)                      48 (55.2)      0.222
                             Sputum                            38 (34.5)                  6 (26.1)                       32 (36.8)      0.241
                             Dyspnea                           37 (33.6)                  13 (56.5)                      24 (27.6)      0.010
                             Diarrhea                          11 (10.0)                  1 (4.3)                        10 (11.5)      0.453
                             Nausea/vomiting                   3 (2.7)                    1 (4.3)                        2 (2.3)        0.509
                             Sore throat                       13 (11.8)                  0 (0)                          13 (14.9)      0.066
                             Chest pain                        5 (4.5)                    0 (0)                          5 (5.7)        0.582
                             Altered smell or taste loss       0 (0)                      0 (0)                          0 (0)          1.000
                             Skin lesion                       1 (0.9)                    1 (4.3)                        0 (0)          0.209
  Vital signs on admission                                                                                                              
                             Body temperature, °C              37.2 ± 0.7                 37.9 ± 1.0                     37.3 ± 0.7     0.002
                             Heart rate, beats/min             86.0 ± 13.8                87.6 ± 12.7                    85.5 ± 14.1    0.532
                             Respiratory rate                  21.0 ± 2.8                 23.1 ± 4.7                     20.4 ± 1.7     0.013
                             Systolic BP, mmHg                 128.1 ± 18.6               134.9 ± 18.6                   126.3 ± 18.4   0.058
                             Peripheral oxygen saturation, %   94.1 ± 5.7                 87.7 ± 7.4                     95.8 ± 3.6     \< 0.001
  Radiologic findings                                                                                                                   
                             Chest X-ray only                  34 (30.9)                  6 (26.1)                       28 (32.2)      
                             Chest X-ray and CT                76 (69.1)                  17 (73.9)                      59 (67.8)      
                             Unilateral pneumonia              17 (15.5)                  1 (4.3)                        16 (18.4)      0.078
                             Bilateral pneumonia               46 (41.8)                  13 (56.5)                      33 (37.9)      
                             Multiple ground-glass opacity     39 (35.5)                  9 (39.1)                       30 (34.5)      
  Treatment in hospital                                                                                                                 
                             Antibiotics                       108 (98.2)                 23 (100)                       85 (97.7)      0.624
                             Lopinavir/ritonavir               106 (96.4)                 22 (95.7)                      84 (96.6)      0.614
                             Hydroxychloroquine                91 (82.7)                  23 (100)                       68 (78.2)      0.011
                             Glucocorticoid                    21 (19.1)                  15 (65.2)                      6 (16.6)       \< 0.001
  Clinical outcomes                                                                                                                     
                             Death                             8 (7.3)                    8 (34.8)                       0 (0)          1.000
  Causes of mortality                                                                                                                   
                             Respiratory failure               4 (3.6)                    4 (17.4)                       0 (0)          1.000
                             Septic shock                      4 (3.6)                    4 (17.4)                       0 (0)          1.000

Data are presented as the mean ± standard deviation or number (%).

COVID-19 = coronavirus disease 2019, BP = blood pressure, CT = computed tomography.

The patients in the severe group were significantly older than the patients in the non-severe group (68.0 ± 11.9 vs. 53.9 ± 17.0, respectively, *P* \< 0.001). The severe group was significantly more likely to have diabetes mellitus (60.9% vs. 17.2%, respectively, *P* = 0.001) and hypertension (52.2% vs. 28.7%, respectively, *P* = 0.033). On admission, body temperature (37.9°C ± 1.0°C vs. 37.3°C ± 0.7°C, respectively, *P* = 0.002) and respiration rate (23.1 ± 4.7 vs. 20.4 ± 1.7 breaths per minute, respectively, *P* = 0.013) were significantly higher in the severe group than the non-severe group. Peripheral oxygen saturation was significantly lower in the severe group than the non-severe group (87.7 ± 7.4 vs. 95.8 ± 3.6, respectively, *P* \< 0.001). It was difficult to detect meaningful differences in radiologic findings between patients in the severe group and those who were not.

Laboratory findings
-------------------

Laboratory findings on hospital admission are summarized in [Table 2](#T2){ref-type="table"}. In complete blood counts, white blood cell count (8.2 ± 3.4 vs. 6.3 ± 3.2, respectively, *P* = 0.017) and neutrophil count (7.1 ± 3.4 vs. 4.1 ± 3.0, respectively, *P* \< 0.001) were higher in the severe group than the non-severe group. Lymphocyte count (0.7 ± 0.3 vs. 1.6 ± 0.7, respectively, *P* \< 0.001) and platelet count (184.7 ± 75.3 vs. 259.8 ± 104.6, respectively, *P* = 0.002) were significantly lower in the severe group than the non-severe group. With regard to blood chemistry, albumin level was significantly lower in the severe group than the non-severe group (3.1 ± 0.4 vs. 3.9 ± 0.5 g/dL, respectively, *P* \< 0.001). Concentrations of aspartate aminotransferase, total bilirubin, blood urea nitrogen, LDH, and creatine kinase-MB (CK-MB) were significantly higher in the severe group than the non-severe group. With regard to infection-related markers, C-reactive protein level was significantly higher in the severe group than the non-severe group (15.5 ± 8.8 vs. 3.3 ± 6.2 mg/L, respectively, *P* \< 0.001), although procalcitonin level was not significantly different between the two groups (2.2 ± 5.6 vs. 0.1 ± 0.1 ng/mL, respectively, *P* = 0.094). Three cases of bacterial co-infection (2 cases of *Klebsiella pneumonia*, 1 case of *Clostridium difficile*) were identified in the non-severe group. Duration of viral shedding was not different between the two groups.

###### Laboratory findings on admission in patients with COVID-19
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  Variables                             All patients (n = 110)                      Severe group (n = 23)              Non-severe group (n = 87)   *P* value                     
  ------------------------------------- ------------------------------------------- ---------------------------------- --------------------------- --------------- ------------- ----------
  Complete blood count (normal range)                                                                                                                                            
                                        White blood cell count, ×10^9^/L (4--10)    6.7 ± 3.3                          8.2 ± 3.4                   6.3 ± 3.2       0.017         
                                                                                    \< 4                               16 (14.5)                   1 (4.3)         15 (17.2)     0.007
                                                                                    4--10                              81 (73.6)                   15 (65.2)       66 (75.9)     
                                                                                    \> 10                              13 (11.8)                   7 (30.4)        6 (6.9)       
                                        Neutrophil count, ×10^9^/L (1.8--6.3)       4.7 ± 3.3                          7.1 ± 3.4                   4.1 ± 3.0       \< 0.001      
                                                                                    \> 6.3                             24 (21.8)                   13 (56.5)       11 (12.6)     \< 0.001
                                        Lymphocyte count, ×10^9^/L (1.1--3.2)       1.4 ± 0.7                          0.7 ± 0.3                   1.6 ± 0.7       \< 0.001      
                                                                                    \< 0.8                             24 (21.8)                   15 (65.2)       9 (10.3)      \< 0.001
                                        Hemoglobin, g/dL (12--16)                   13.0 ± 1.5                         13.2 ± 1.8                  12.9 ± 1.4      0.385         
                                                                                    \< 12                              22 (20.0)                   4 (17,4)        18 (20.7)     0.491
                                        Platelets, ×10^9^/L (140--440)              244.1 ± 103.5                      184.7 ± 75.3                259.8 ± 104.6   0.002         
                                                                                    \< 140                             19 (17.3)                   10 (43.5)       9 (10.3)      \< 0.001
  Blood chemistry (normal range)                                                                                                                                                 
                                        Albumin, g/dL (3.5--5)                      3.7 ± 0.6                          3.1 ± 0.4                   3.9 ± 0.5       \< 0.001      
                                                                                    \< 3.5                             38 (35.2)                   20 (87)         18 (21.2)     \< 0.001
                                        Alanine aminotransferase, IU/L (0--40)      36.6 ± 46.6                        54.5 ± 84.1                 31.9 ± 28.9     0.215         
                                                                                    \> 40                              31 (28.2)                   13 (56.6)       18 (20.7)     0.001
                                        Aspartate aminotransferase, IU/L (10--35)   45.1 ± 47.8                        81.3 ± 83.3                 35.5 ± 26.0     0.016         
                                                                                    \> 35                              29 (26.4)                   6 (26.1)        23 (22.9)     0.973
                                        Total bilirubin, mg/dL (0.1--1.2)           0.9 ± 0.5                          1.1 ± 0.6                   0.8 ± 0.4       0.014         
                                                                                    \> 1.2                             18 (16.8)                   7 (30.4)        11 (13.1)     0.054
                                        Blood urea nitrogen, mg/dL (8--23)          15.6 ± 9.0                         21.7 ± 15.6                 13.9 ± 5.4      0.027         
                                                                                    \> 23                              13 (11.8)                   8 (34.8)        5 (5.7)       0.001
                                        Creatinine, mg/dL (0.5--0.9)                0.9 ± 0.5                          1.1 ± 0.9                   0.8 ± 0.2       0.174         
                                                                                    \> 0.9                             36 (32.7)                   11 (47.8)       25 (28.7)     0.083
                                        Creatinine phosphokinase, IU/L (1--145)     108.4 ± 155.2                      152.2 ± 182.0               95.0 ± 145.0    0.150         
                                                                                    \> 145                             9 (10.6)                    4 (20.0)        5 (7.7)       0.127
                                        Lactate dehydrogenase, IU/L (150--550)      625.9 ± 331.7                      996.7 ± 497.3               527.7 ± 171.9   \< 0.001      
                                                                                    \> 550                             51 (48.6)                   21 (95.5)       30 (36.1)     \< 0.001
                                        CK-MB, ng/mL (0.6--6.3)                     3.2 ± 3.3                          5.3 ± 4.1                   1.9 ± 1.8       0.003         
                                                                                    \> 6.3                             7 (15.6)                    6 (33.3)        1 (3.7)       0.012
  Coagulation function                                                                                                                                                           
                                        Prothrombin time, sec (10.4--13.3)          13.0 ± 17.4                        16.3 ± 26.7                 10.7 ± 4.2      0.278         
                                                                                    \> 13.3                            10 (20.4)                   7 (35.0)        3 (10.3)      0.068
                                        D-dimer, μg/mL (0--0.5)                     4.4 ± 16.5                         8.6 ± 25.3                  1.4 ± 1.8       0.029         
                                                                                    \> 0.5                             29 (76.3)                   16 (100.0)      13 (59.1)     0.005
  Infection biomarkers (normal range)                                                                                                                                            
                                        C-reactive protein, mg/dL (0--0.5)          5.8 ± 8.4                          15.5 ± 8.8                  3.3 ± 6.2       \< 0.001      
                                                                                    \> 0.5                             68 (66.7)                   21 (100)        47 (58.0)     \< 0.001
                                        Procalcitonin, ng/mL (0--0.5)               0.49 ± 2.6                         2.2 ± 5.6                   0.1 ± 0.1       0.094         
                                                                                    \> 0.5                             7 (6.5)                     6 (27.3)        1 (1.2)       \< 0.001
                                        Co-infection                                                                                                                             
                                                                                    Bacteria                           3 (2.7)                     0 (0)           3 (3.4)       1.000
                                                                                    Other viruses                      0                           0               0             1.000
                                        Viral shedding                                                                                                                           
                                                                                    Duration of viral shedding, days   33.1 ± 10.0                 34.2 ± 10.1     32.9 ± 10.0   0.659

Data are presented as the mean ± standard deviation or number (%).

COVID-19 = coronavirus disease 2019, CK-MB = creatine-kinase MB.

Prognostic factors for severe COVID-19
--------------------------------------

Multivariable analysis using variables with *P* \< 0.05 in univariable analysis ([Table 3](#T3){ref-type="table"}) and the final logistic regression model demonstrated that diabetes mellitus (odds ratio \[OR\], 19.15; 95% confidence interval \[CI\], 1.90--193.42; *P* = 0.012), body temperature ≥ 37.8°C (OR, 10.91; 95% CI, 1.35--88.36; *P* = 0.025), peripheral oxygen saturation \< 92% (OR, 33.31; 95% CI, 2.45--452.22; *P* = 0.008), and CK-MB \> 6.3 (OR, 56.84; 95% CI, 2.64--1,223.78; *P* = 0.010) on admission were associated with greater risk of severe COVID-19 ([Table 4](#T4){ref-type="table"}). The rates of severe disease increased for patients with diabetes mellitus, body temperature ≥ 37.8°C, peripheral oxygen saturation ≤ 92%, and CK-MB \> 6.3 ([Fig. 2](#F2){ref-type="fig"}). The likelihood of development of severe COVID-19 increased with increasing number of prognostic factors (*P* \< 0.001, test for trend) ([Fig. 3](#F3){ref-type="fig"}).

###### Univariable analysis of prognostic factors for severe COVID-19
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  Prognostic factors                OR (95% CI)          *P* value             
  --------------------------------- -------------------- --------------------- ----------
  Age, yr                           1.07 (1.03--1.11)    0.001                 
                                    0--39                Reference             
                                    40--49               0.00 (0.0--0.0)       1.000
                                    50--59               0.40 (0.03--4.70)     0.463
                                    60--69               3.46 (0.65--18.29)    0.145
                                    ≥ 70                 8.14 (1.57--42.33)    0.013
  Male, sex                         2.43 (0.95--6.22)    0.065                 
  Diabetes mellitus                 7.47 (2.73--20.40)   \< 0.001              
  Hypertension                      2.71 (1.06--6.93)    0.038                 
  Body temperature, °C              2.54 (1.35--4.78)    0.004                 
                                    \< 37.8              Reference             
                                    ≥ 37.8               6.36 (2.32--17.43)    \< 0.001
  Respiratory rate                  1.42 (1.14--1.76)    \< 0.001              
                                    ≤ 20                 Reference             
                                    \> 20                8.11 (2.94--22.36)    \< 0.001
  Peripheral oxygen saturation, %   0.75 (0.66--0.85)    \< 0.001              
                                    ≥ 92                 Reference             
                                    \< 92                17.71 (5.82--53.87)   \< 0.001
  Albumin                           0.03 (0.01--0.13)    \< 0.001              
                                    ≥ 3.5                Reference             
                                    \< 3.5               24.82 (6.63--92.92)   \< 0.001
  Total bilirubin                   3.19 (1.22--8.35)    0.018                 
                                    ≤ 1.2                Reference             
                                    \> 1.2               2.71 (1.05--7.00)     0.040
  CK-MB                             1.52 (1.12--2.01)    0.007                 
                                    ≤ 6.3                Reference             
                                    \> 6.3               13.0 (1.41--120.27)   0.024

COVID-19 = coronavirus disease 2019, OR = odds ratio, CI = confidence interval, CK-MB = creatine-kinase MB.

###### Multivariable logistic regression analysis of prognostic factors for severe COVID-19
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  Prognostic factors                    Multivariable model 1^a^   Multivariable model 2^b^                                                 
  ------------------------------------- -------------------------- -------------------------- ------------------------ -------------------- -------
  Age, yr                                                                                                                                   
                                        ≥ 70                                                                           3.37 (0.26--43.58)   0.352
  Male, sex                                                                                   2.98 (0.23--38.81)       0.404                
  Diabetes mellitus                     6.53 (2.26--18.87)         0.001                      19.15 (1.90--193.42)     0.012                
  Hypertension                          1.44 (0.49--4.26)          0.508                      1.00 (0.09--10.78)       0.999                
  Body temperature ≥ 37.8°C             8.27 (2.62--26.09)         \< 0.001                   10.91 (1.35--88.36)      0.025                
  Peripheral oxygen saturation \< 92%   15.39 (4.83--48.98)        \< 0.001                   33.31 (2.45--452.22)     0.008                
  Albumin \< 3.5                        27.21 (6.98--106.10)       \< 0.001                   5.36 (0.49--59.32)       0.171                
  Total bilirubin \> 1.2                2.53 (0.92--6.97)          0.073                      5.92 (0.69--51.01)       0.106                
  CK-MB \> 6.3                          13.00 (1.41--120.27)       0.024                      56.84 (2.64--1,223.78)   0.010                

COVID-19 = coronavirus disease 2019, OR = odds ratio, CI = confidence interval, CK-MB = creatine-kinase MB.

^a^Adjusted for age, sex; ^b^Adjusted for age, sex, diabetes mellitus, hypertension, body temperature, peripheral oxygen saturation, albumin, total bilirubin, and CK-MB.

![Comparison of rates of severe COVID-19 using categorical variables.\
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![Rate of patients with severe COVID-19 according to the presence of prognostic factors.\
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DISCUSSION
==========

Among the 110 patients with COVID-19, 23 (20.9%) had severe disease and the in-hospital case fatality rate was 7.3% in this study. We showed that the presence of diabetes mellitus, body temperature ≥ 37.8°C, peripheral oxygen saturation \< 92%, and CK-MB \> 6.3 were independent predictors of severe disease in hospitalized COVID-19 patients. To our knowledge, this is the first study to evaluate the prognostic factors of severe COVID-19 in Korea.

Diabetes mellitus is a major public health issue, with an estimated global prevalence of 9.3% in 2019.[@B10] A population-based cohort study showed that type 2 diabetes increased the risk of death associated with pneumonia, and hyperglycemia on admission was associated with increased mortality for both diabetic and nondiabetic patients with community-acquired pneumonia.[@B11] Yang et al.[@B12] reported that diabetes and ambient hyperglycemia are independent risk factors for death and morbidity in SARS patients. Diabetes also results in immune dysregulation and more severe and prolonged lung pathology in Middle East respiratory syndrome.[@B13] The main mechanisms underlying the poorer clinical outcomes in cases of infections associated with diabetes mellitus are as follows: 1) decreased T lymphocyte response; 2) decreased neutrophil function; 3) disorders of humoral immunity; and 4) depression of the antioxidant system.[@B14] In a recent study, COVID-19 patients without other comorbidities but with diabetes were shown to be at greater risk of severe disease as assessed by organ damage, inflammatory factors, and hypercoagulability. In addition, COVID-19 patients with diabetes are at high risk for disease progression.[@B15] The results of the present study suggested that the progression of COVID-19 is influenced by diabetes mellitus. Physicians should pay close attention to whether diabetic patients with COVID-19 show rapid clinical deterioration.

Body temperature is one of the variables included in the pneumonia severity index[@B16] and systemic inflammatory response syndrome (SIRS),[@B17] which can predict clinical outcomes in pneumonia. The febrile response is thought to be mediated by endogenous factors, called endogenous pyrogens. Pyrogenic cytokines, such as tumor necrosis factor (TNF), interleukin (IL)-1, IL-6, and interferons (IFNs), are released in response to exogenous stimuli, such as bacterial or viral products and toxins.[@B18] In COVID-19, the levels of the proinflammatory cytokines IL-1β, IL-4, IL-6, IL-10, IFN-γ, and TNF-α are significantly higher in severe cases than in mild cases.[@B19] The results of the present study suggested that critical COVID-19 patients have elevated levels of inflammatory cytokines, which increase body temperature.

Low peripheral oxygen saturation was shown to be an independent prognostic factor for severe COVID-19.[@B8] Many COVID-19 patients experience rapid respiratory failure and hypoxemia without any signs of dyspnea, which is referred to as silent hypoxemia.[@B20] This unique characteristic of COVID-19 makes it difficult to predict clinical deterioration accurately using traditional scores, such as quick sequential organ failure assessment and SIRS. As COVID-19 is a highly contagious infectious disease, medical staff tend to have less contact with patients. Therefore, the discovery of a worsening condition in patients may be delayed. From this viewpoint, peripheral oxygen saturation measured immediately upon hospitalization through pulse oximetry can be used as a convenient and accurate marker for the prediction of clinical deterioration in COVID-19.

Cardiac injury is associated with death, and severity of COVID-19 is associated with acute cardiac injury. In the systemic review of the 28 studies with 4,189 confirmed COVID-19 patients, severe COVID-19 infection was associated with high cardiac injury related markers, such as troponin, CK-MB, and myoglobin. And also cardiac injury in COVID-19 were related with higher mortality (OR, 3.85; 95% CI, 2.13--6.96; *P* \< 0.001).[@B21] It has been known that, the SARS-CoV-2 invades human cells via the receptor angiotensin converting enzyme II (ACE2). ACE2 is expressed in the lung, heart, esophagus, kidney, bladder, and ileum. Thus, organs that express ACE2 are vulnerable to SARS-CoV-2 infection.[@B22] Therefore, the measurement of cardiac damage markers on admission is needed in patients with COVID-19, which predict the prognosis of COVID-19.

There are several Chinese studies demonstrating the risk factors for severity of COVID-19. Li et al.[@B5] reported that elder age, hypertension, high cytokine levels, and high LDH levels were associated with severe COVID-19 inpatients in Wuhan. A study in Anhui, China revealed that low fingertip oxygen saturation, and decreased CD4 cell count were independent risk factors for severe COVID-19 patients.[@B8] Diabetes, and maximum body temperature admission were risk factors for progression of COVID-19.[@B15][@B23] The predictors of severe disease progression on Korean patients and those in Chinese patients were not much different.

This study had several limitations. First, this was a retrospective study conducted in a single center in Korea, which subjected only hospitalized patients. Therefore, these results cannot be generalized to all COVID-19 patients. Second, antiviral agents and corticosteroid usage were not included as variables in this study. Our research focused on the baseline clinical characteristics and laboratory findings related to worsening of the patients\' condition due to severe disease and not on treatment. Third, selection bias could not be avoided because population-based data were not used. The disease severity of patients may vary between hospitals in the same region. Fourth, proinflammatory cytokines and early CD8+ T-cell response that can be associated with disease severity, were not measured in this study.

In conclusion, we found that the presence of diabetes mellitus, body temperature ≥ 37.8°C, peripheral oxygen saturation \< 92%, and CK-MB \> 6.3 are independent predictors of severe disease in hospitalized COVID-19 patients. The likelihood of progression to severe COVID-19 increased with an increasing number of prognostic factors. Appropriate assessment of prognostic factors and close monitoring to provide the necessary interventions at the appropriate time in high-risk patients may reduce the case fatality rate of COVID-19.
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